Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
Condition(s):Epidermolysis BullosaLast Updated:September 27, 2019Terminated
Hide Studies Not Open or Pending
Condition(s):Epidermolysis BullosaLast Updated:September 27, 2019Terminated
Condition(s):Epidermolysis BullosaLast Updated:November 4, 2019Terminated
Condition(s):Epidermolysis BullosaLast Updated:January 13, 2020Completed
Condition(s):Umbilical Cord IssueLast Updated:July 25, 2023Completed
Condition(s):Erectile DysfunctionLast Updated:August 29, 2018Completed
Condition(s):Spinal Cord Injuries; Spine Disease; StrokeLast Updated:January 18, 2024Recruiting
Condition(s):Post Dermatological Surgery ScarsLast Updated:September 9, 2015Completed
Condition(s):Surgical Site InfectionLast Updated:May 2, 2022Terminated
Condition(s):Xerostomia; Sjogren’s SyndromeLast Updated:August 2, 2018Completed
Condition(s):Xerosis CutisLast Updated:January 2, 2024Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.